Business

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#Business #Drug development #Drug discovery #Enabling technologies #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA #Stem cells

GSK and CureVac in mRNA technology collaboration

27 July 2020 Image: CDC GlaxoSmithKline and CureVac are collaborating for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Business #Clinical trials #Computational chemistry #Drug development

Cytel makes access to clinical trial designs easier

24 July 2020 Image: Joshua Sortino Cytel’s East Alloy platform is a web-native extension of the company’s East software for adaptive clinical trial design and analysis. By leveraging the speed of cloud computing and the pace of SaaS delivery, East Alloy enables easy implementation of computationally intensive Bayesian… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Precision medicine #RNA #Therapeutics

Over £100m UK cash boost to produce millions of doses of COVID-19 vaccine

The UK’s capability to manufacture vaccines has received a substantial boost, as the UK government has announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. The investment will fund a Cell and Gene Therapy Catapult Manufacturing Innovation… Read More

#Covid-19 #News

#Academic #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Top Ten UK organisations for animal research announced

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Business #Cell therapy #Drug discovery #Gene therapy #Target validation

Thermo Fisher Scientific looks to speed up cell and gene manufacturing

22 July 2020 Image: ThisisEngineering RAEng Thermo Fisher Scientific’s latest launch has been designed to allow fast cGMP-compatible cell and gene therapy manufacturing. Developed as the first-ever all-inclusive solution to simplify and optimise the cGMP equipment installation and validation process, the Thermo Scientific Cell Therapy Systems (CTS) Series… Read More

#News

#Assay development optimisation & technology #Business #Drug development #Drug discovery #Drug targets #High throughput screening #Immunology #Lead discovery #Screening #Stem cells #Therapeutics

AbCellera agreement to use humanised mice platform for antibody discovery

21 July 2020 Image: Henry Lai AbCellera has entered into an agreement with Alloy Therapeutics to use the ATX-Gx humanised mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. Under the terms of the agreement, AbCellera will offer its biotech and pharma partners… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News

#Academic #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK pharma body says COVID-19 vaccine may still be many months away

Image: Dimitri Houtteman A COVID-19 vaccine being developed by Oxford University and AstraZeneca has generated an immune response in a study of roughly 1,000 patients, according to interim results. The Association of the British Pharmaceutical Industry (ABPI) has responded to the results of the Oxford – AstraZeneca vaccine… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #RNA #Stem cells

Study shows Oxford coronavirus vaccine produces strong immune response

A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Protein chemistry / Proteomics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Sphere Fluidics and Heriot-Watt University develop droplet generator instrumentation

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of… Read More

#News

#Biologics / Biotechnology #Business #Clinical trials #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

UK secures portfolio of promising vaccines candidates from BioNTech/Pfizer alliance

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising Covid-19 vaccine candidates. The UK government has agreed significant partnerships with leading pharmaceutical and vaccine companies BioNTech/Pfizer and Valneva that are developing new vaccines to protect people against… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Lead discovery #Regulatory

Phase 1 clinical trial of COVID-19 vaccine begins at University of Queensland

The next critical phase for The University of Queensland’s (UQ) COVID-19 vaccine is underway, with the research effort moving out of the lab and into human trials. Healthy adult volunteers have received the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist,… Read More

#Covid-19 #News

#Animal models #Business #Drug discovery #Drug targets #Lead discovery #RNA #System biology #Toxicology

Humane Society International/UK says government must move away from animal use

According to the Humane Society International/UK (HSI/UK), Home Office statistics reveal that the number of animals in British laboratories has stayed broadly the same almost a decade after the government pledged to reduce animal use. It says that UK laboratories completed a total of 3.4 million procedures in… Read More

#News

#Assay development & optimisation #Automation / robotics #Biobanking #Business #Drug discovery #Genomics #Lead discovery #Oncology #Protein chemistry / Proteomics

SPT Labtech opens new office to maximise on Japanese biotech growth

15 July 2020 This is the company’s second site in the APAC region, headed by Masahiro Matsushita. The expansion follows long-standing partnerships with Japanese life science distributors. The move was motivated, in part, by growing biotech and healthcare markets in Japan. The increasing importance of the Japanese life… Read More

#News

#Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #Gene therapy #Imaging #PCR #RNA

LGC expands SARS-CoV-2 molecular solutions to full genome coverage

Image: Fusion Medical Automation Initially designed to target the published CDC and WHO consensus sequences, the AccuPlex SARS-CoV-2 Verification Panel and Reference Material Kit are available with full SARS-CoV-2 viral genome coverage. This expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining the safety features and… Read More

#Covid-19 #News